Genetic Variants in the Apoptosis Gene BCL2L1 Improve Response to Interferon-Based Treatment of Hepatitis C Virus Genotype 3 Infection

Louise Nygaard Clausen 1,2,3,*, Nina Weis 1,4, Steen Ladelund 2, Lone Madsen 5, Suzanne Lunding 6, Britta Tarp 7, Peer Brehm Christensen 8, Henrik Bygum Krarup 9, Axel Møller 10, Jan Gerstoft 11, Mette Rye Clausen 12, Thomas Benfield 1,2,4 and the DANHEP group 13

1 Department of Infectious Diseases, Copenhagen University Hospital, 2650 Hvidovre, Denmark; E-Mails: ninaweis@dadlnet.dk (N.W.); tlb@dadlnet.dk (T.B.)
2 Clinical Research Centre, Copenhagen University Hospital, 2650 Hvidovre, Denmark; E-Mail: steen.ladelund.01@regionh.dk
3 Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre and Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
4 Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
5 Department of Gastroenterology, Køge Hospital, 4600 Køge, Denmark; E-Mail: logm@regionsjaelland.dk
6 Department of Infectious Diseases, Hillerød Hospital, 3400 Hillerød, Denmark; E-Mail: lunding@dadlnet.dk
7 Diagnostic Center, Silkeborg Regional Hospital, 8600 Silkeborg, Denmark; E-Mail: brittarp@rm.dk
8 Department of Infectious Diseases, Odense University Hospital, 5230 Odense, Denmark; E-Mail: peer.christensen@dadlnet.dk
9 Department of Gastroenterology and Department of Clinical Biochemistry, Section for Molecular Diagnostics, Aalborg University Hospital, 9100 Aalborg, Denmark; E-Mail: h.krarup@rn.dk
10 Department of Medicine, Kolding Regional Hospital, 6000 Kolding, Denmark; E-Mail: Axel.Moeller@slb.regionsyddanmark.dk
11 Department of Infectious Diseases and Rheumatology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark; E-Mail: jan.gerstoft@rh.regionh.dk
12 Department of Hepatology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark; E-Mail: metteryeclausen@hotmail.com
13 The DANHEP group (see Appendix 1)
Abstract: Genetic variation upstream of the apoptosis pathway has been associated with outcome of hepatitis C virus (HCV) infection. We investigated genetic polymorphisms in the intrinsic apoptosis pathway to assess their influence on sustained virological response (SVR) to pegylated interferon-α and ribavirin (pegIFN/RBV) treatment of HCV genotypes 1 and 3 infections. We conducted a candidate gene association study in a prospective cohort of 201 chronic HCV-infected individuals undergoing treatment with pegIFN/RBV. Differences between groups were compared in logistic regression adjusted for age, HCV viral load and interleukin 28B genotypes. Four single nucleotide polymorphisms (SNPs) located in the B-cell lymphoma 2-like 1 (BCL2L1) gene were significantly associated with SVR. SVR rates were significantly higher for carriers of the beneficial rs1484994 CC genotypes. In multivariate logistic regression, the rs1484994 SNP combined CC + TC genotypes were associated with a 3.4 higher odds ratio (OR) in SVR for the HCV genotype 3 (p = 0.02). The effect estimate was similar for genotype 1, but the association did not reach statistical significance. In conclusion, anti-apoptotic SNPs in the BCL2L1 gene were predictive of SVR to pegIFN/RBV treatment in HCV genotypes 1 and 3 infected individuals. These SNPs may be used in prediction of SVR, but further studies are needed.

Keywords: apoptosis in HCV treatment; prediction of sustained virological response; host genetics; interferon and apoptosis interaction; spontaneous HCV resolution

1. Introduction

Hepatitis C virus (HCV) is a major global health issue, with 170 million individuals chronically infected and 350,000 deaths annually [1].

Apoptosis, also called programmed cell death, is one of the immune system’s responses to viral infection. Many viruses, including HCV, make use of a variety of mechanisms to neutralise interferon (IFN) secretion and block genes participating in apoptosis to escape host immune attack [2].

Apoptosis can be induced via the extrinsic or the intrinsic pathways. The intrinsic pathway, which is the aim of this study, is induced by mitochondria in response to DNA damage, oxidative stress, and viral proteins [3]. Apoptosis via the intrinsic pathway is amplified by pro-apoptotic genes (Bax, Bak, Bad, Box), whereas proteins such as B-cell lymphoma-2 (BCL2) and B-cell lymphoma 2-like 1 (BCL2L1) are anti-apoptotic. BCL2L1 and BCL2 converge at the mitochondrial permeability
transition pore, which regulates the release of apoptotic regulatory proteins, such as procaspase-9 and cytochrome C [4], to inhibit apoptosis. Both the extrinsic and the intrinsic apoptosis pathways are integrated into a common final pathway resulting in caspase-dependent apoptosis [3]. Glucocorticoid-induced tumour necrosis factor (TNF) receptor-related protein ligand (GITRL) is a newly identified member of the TNF receptor superfamily [5], and its interaction with GITR enhances apoptosis via the intrinsic pathway, possibly through natural killer (NK) cell-induced inhibition of BCL2L1 [6]. We screened the pathway that initiates at the GITR ligand and via CD27-binding protein (CD27BP) terminates at the mitochondrial transmembrane proteins BCL2L1 and BCL2.

Hence, we investigated single-nucleotide polymorphisms (SNPs) in the intrinsic apoptosis pathway, hypothesising that they may influence the rates of SVR.

2. Results

2.1. Host Genotypes

We genotyped 30 SNPs in four genes (GITRL, CD27BP, BCL2L1, BCL2) (Table S1) and removed monomorphic SNPs (n = 10) and those in Hardy-Weinberg disequilibrium (p-value < 0.01 (n = 1, rs6121038)). Genotyping failed for 3 SNPs, leaving 16 SNPs with a call rate >95% eligible for the analysis. All SNPs showed distinct clustering. After applying an FDR threshold of <0.05, a total of 4 SNPs were found to be associated with treatment response (Table S2); all 4 were found in the BCL2L1 gene and were in complete linkage disequilibrium (LD) with each other. Below, we report only the results of the statistically most significant SNP, rs1484994 (hereafter referred to as BCL2L1).

2.2. Treatment Responses

2.2.1. Study Population and Association of BCL2L1 with SVR and HCV Viral Load

The study cohort consisted of 201 white Europeans; of these, 117 achieved SVR, and 84 failed to respond to treatment, corresponding to an overall SVR rate of 58% (95% CI; 48, 69). The main characteristics are presented in Table 1. Treatment was initiated between January 2000 and November 2009, and SVR was 46% (95% CI; 41, 51) and 70% (95% CI; 65, 75) for genotypes 1 and 3, respectively (Table 2). For HCV genotype 1, the SVR rates were significantly higher for carriers of the beneficial BCL2L1 and IL28B CC genotypes compared to the non-CC genotypes (Table 2). All individuals (n = 5) with HCV genotype 3 that carried the BCL2L1 CC genotype achieved SVR (Figure 1). One-hundred-and-eighty-two individuals had a measurable HCV viral load (VL) within a year of treatment initiation (20, interquartile range (IQR, 0, 64) days). For genotype 1, \( \log_{10} \) HCV VL (international units (IU)/mL) was lower for carriers of the BCL2L1 CC genotype (median, 5.9; IQR, 5.3, 6.3) compared with TC and TT carriers (median, 6.5 (IQR 5.4, 7.0); 6.5 (IQR 5.9, 6.9), p = 0.1), respectively. For genotype 3, HCV VL was lower for carriers of the BCL2L1 CC genotype (median, 5.3; IQR, 5.0, 6.7) compared with TC and TT carriers (median, 6.1 (IQR 5.5, 6.4); 5.8 (IQR 5.0, 6.3), p = 0.7).
Table 1. Main characteristics of 201 individuals with chronic hepatitis C virus infection.

| Characteristic | Value, n (%) |
|----------------|--------------|
| Male           | 132 (66)     |
| HCV genotype   |              |
| 1              | 100 (50)     |
| 3              | 101 (50)     |
| Age at treatment initiation, years (median, IQR) | 48 (43, 53) |
| HCV viral load at treatment initiation, log (IU/mL) (median, IQR) | 6.1 (5.4, 6.7) |
| IL28B genotype, rs12979860 (n = 198 *) |            |
| CC             | 75 (38)      |
| CT             | 106 (53)     |
| TT             | 17 (9)       |
| Completion of treatment |              |
| As scheduled   | 118 (59)     |
| With dose reduction | 36 (18)    |
| Terminated before scheduled | 47 (23) |
| Fibrosis (n = 102 **) |            |
| None/light     | 43 (39)      |
| Moderate/advanced | 30 (32)  |
| Cirrhosis      | 29 (29)      |
| Ribavirin dose, mg/day (n = 199 ***): | |
| ≤800           | 78 (39)      |
| 1000           | 57 (29)      |
| ≥1200          | 64 (32)      |
| Pegylated interferon α |          |
| 2a             | 133 (66)     |
| 2b             | 68 (34)      |

HCV, hepatitis C virus; IQR, interquartile range; IL28B, interleukin 28B. * Three individuals could not be genotyped for IL28B; ** 99 individuals had missing information regarding fibrosis; *** one individual did not receive ribavirin.

Table 2. Comparison of sustained virological treatment response rates in 201 individuals with chronic hepatitis C virus infection.

| Characteristic | HCV Genotype 1, n = 100 | HCV Genotype 3, n = 101 |
|----------------|--------------------------|-------------------------|
|                | SVR, n = 46 (46%)        | SVR, n = 71 (70%)       |
|                | Non-Response, n = 54 (54%) | Non-Response, n = 30 (30%) |
| p-Value        |                          |                         |
| Sex            |                          |                          |
| Female         | 16 (50)                  | 26 (70)                 |
| Male           | 30 (44)                  | 45 (70)                 |
| Age at treatment initiation |          |                          |
| <40 years      | 14 (58)                  | 36 (82)                 |
| ≥40 years      | 32 (42)                  | 35 (61)                 |
| HCV viral load at treatment initiation * |          |                          |
| <5.8 log10 IU/mL | 16 (53)                  | 38 (79)                 |
| ≥5.8 log10 IU/mL | 30 (43)                  | 33 (62)                 |

p-Values: 1 = not significant, 0.03 = significant, 0.06 = marginally significant.
Table 2. Cont.

| Characteristic | HCV Genotype 1, n = 100 | HCV Genotype 3, n = 101 |
|---------------|-------------------------|-------------------------|
|               | SVR, n = 46 (46%)       | SVR, n = 71 (70%)       |
|               | Non-Response, n = 54 (54%) | Non-Response, n = 30 (30%) |
|               | p-Value                 | p-Value                 |
| IL28B genotype |                         |                         |
| CC            | 19 (70)                 | 32 (67)                 |
|               | 8 (30)                  | 16 (33)                 |
| TC            | 22 (37)                 | 33 (70)                 |
|               | 37 (63)                 | 14 (30)                 |
| TT            | 3 (27)                  | 6 (100)                 |
|               | 8 (73)                  | 0                       |
| BCL2L1 genotype |                        |                         |
| TT            | 17 (36)                 | 35 (65)                 |
|               | 30 (64)                 | 19 (35)                 |
| TC            | 15 (41)                 | 31 (74)                 |
|               | 22 (59)                 | 11 (26)                 |
| CC            | 10 (83)                 | 5 (100)                 |
|               | 2 (17)                  | 0                       |

Non-response comprises non-responders and relapers. HCV, hepatitis C virus; SVR, sustained virological response; IL28B, interleukin 28B rs12979860 single-nucleotide polymorphism (SNP); BCL2L1, B-cell lymphoma 2-like 1, rs1484994 SNP. * HCV RNA viral load was not measured within 365 days of treatment initiation for 10 individuals.

Figure 1. Rates of sustained virological responses according to interleukin-28B and BCL2L1 genotypes in individuals infected with hepatitis C virus genotypes 1 or 3.

2.2.2. Logistic Regression Analysis of BCL2L1 Association to SVR

The distribution of the BCL2L1 C alleles indicated a dominant effect of the C allele on SVR for both HCV genotypes 1 and 3 (Tables 2 and S3); therefore, the CC and TC genotypes were combined. In a multivariate logistic regression stratified by HCV genotype, the BCL2L1 CC + TC genotype was associated with a 3.4 higher OR in SVR for HCV genotype 3 ($p = 0.02$) (Table 3). The effect estimate was similar for genotype 1, but the association did not reach statistical significance. For genotype 1, sex, age, and HCV VL at treatment initiation were not significantly associated with SVR. For genotype 3-infected individuals, age < 40 years at treatment initiation (adjusted odds ratio (aOR), 3.1 (1.1, 9.2)) and HCV VL < 5.8 log10 IU/mL (aOR, 3.4 (1.1, 10.7)) were associated with SVR. All four BCL2L1 SNPs associated with SVR in the initial analyses, remained significantly associated with SVR in the
multivariate logistic regression with effect estimates similar to rs1484994. Of note, this is not surprising as the four SNPs are in complete linkage with each other.

Table 3. Multivariate logistic regression of sustained virological response in 182 individuals with chronic hepatitis C virus infection.

| Characteristic | HCV Genotype 1 (n = 91) | HCV Genotype 3 (n = 91) |
|---------------|-------------------------|-------------------------|
|               | Adjusted Odds Ratio (95% CI) | p-Value | Adjusted Odds Ratio (95% CI) | p-Value |
| \textit{IL28B}, rs12979860 | | | |
| TT            | 1 | 0.01 | 1 | 0.6 |
| TC            | 0.97 (0.2, 4.9) | 0.4 (0, 3.1) |
| CC            | 5.7 (1.0, 32.5) | 0.4 (0, 3.4) |
| \textit{IL28B}, rs12979860 | | | |
| TC + TT       | 1 | 0.002 | 1 | 0.8 |
| CC            | 5.9 (1.9, 17.3) | 1.1 (0.4, 3.4) |
| \textit{BCL2L1}, rs1484994 | | | |
| TT            | 1 | 0.049 | 0.06 |
| TC            | 1.5 (0.5, 4.3) | 2.8 (0.9, 9.7) | 0.08 |
| CC            | 9.0 (1.6, 52.3) | 2.9 (0.5, infinity) | 0.4 |
| \textit{BCL2L1}, rs1484994 | | | |
| TT            | 1 | 0.1 | 1 | 0.02 |
| TC + CC       | 2.2 (0.8, 5.9) | 3.4 (1.2, 9.8) |

The model was adjusted for age and HCV viral load at treatment initiation and \textit{IL28B} genotypes. Abbreviations: HCV, hepatitis C virus; CI, confidence interval; \textit{IL28B}, interleukin 28B; \textit{BCL2L1}, B-cell lymphoma 2-like 1.

2.3. Ability of Gene- and Non-Gene Classifiers to Predict Treatment Response

We constructed receiver operating characteristic (ROC) curves for factors associated with SVR (Figure S1). We defined four curves consisting of factors known to predict SVR to evaluate the non-genetic vs. genetic contribution in SVR prediction: the non-gene classifier consisted of the viral and demographic variables HCV VL and age, the two-gene classifier consisted of \textit{IL28B} and \textit{BCL2L1} SNPs, the combined IL28B*non-gene classifier consisted of the \textit{IL28B} SNP, HCV VL and age variables and the two gene*non gene classifier consisted of \textit{IL28B}, \textit{BCL2L1}, HCV VL and age.

In individuals with HCV genotype 1, the curves of the non-gene classifier had an area under the curve (AUC) of 0.60, and the curves of the two-gene classifier had an AUC of 0.74. When combining the non-gene classifier with the two-gene classifier, the AUC increased to 0.79 ($p = 0.003$). In individuals with HCV genotype 3, the genetic effect appeared to be attenuated. The AUC increased from 0.71 for the non-gene classifier to 0.79 for the two-gene classifier *non-gene classifier ($p = 0.3$). The $p$-values refer to comparison with the non-gene classifier.
3. Discussion

Identification of SNPs in the BCL2L1 Gene that Are Predictive of SVR to pegIFN/RBV Treatment of Genotype 3 Chronic Hepatitis C

Our findings, although preliminary, suggest a role for apoptosis in the pegIFN/RBV-mediated elimination of HCV. Interestingly, individuals achieving SVR have been shown to have more apoptotic activity prior to and during pegIFN/RBV treatment compared to individuals with non-response or relapse [7,8]. In line with this, Anatol et al. [9] reported that individuals with non-response to HCV treatment might have higher levels of expression of the anti-apoptotic gene BCL2. Shaker et al. [10] showed an association between an SNP (rs1800477) in BCL2 and SVR in individuals infected with HCV genotype 4. The variant genotype was found to double SVR compared to individuals with the common genotype. Unfortunately, we have repeatedly been unable to genotype rs1800477. Given that IFN stimulates apoptosis and that we observed an effect on SVR for the variant allele of polymorphisms in BCL2L1, we suggest that the degree of IFN-induced apoptosis may be influenced by polymorphisms in anti-apoptotic genes, as shown by us and others [10]. Functional studies will be required to clarify how such polymorphisms may affect the response to treatment.

The treatment paradigm of chronic hepatitis C (CHC) has changed dramatically with the development of direct-acting antivirals (DAAs) targeting different parts of the HCV lifecycle. Interestingly, the NS5B polymerase inhibitor sofosbuvir, combined with RBV and pegIFN, appears to have less activity towards genotype 3 than genotypes 1 and 2 [11–13]. The clinical implication of our findings may be the ability to predict SVR in individuals infected with HCV genotype 3, for whom IL28B has no predictive value. This would allow the better targeting of PEG-IFN/RBV treatment, thus avoiding its unpleasant side effects, and reducing the overall treatment costs. Indeed, a genetic predictor of SVR in this genotype may be helpful when selecting the best treatment strategy. Further, given the high cost of DAAs, pegIFN and ribavirin are expected to remain the standard of care throughout most of the world for many years.

Our study was not designed to clarify whether the identified SNPs upregulate or downregulate apoptotic activity during HCV treatment; nonetheless, we speculate that the polymorphisms in the BCL2L1 gene alter the expression of the anti-apoptotic protein in favour of SVR. Pathogenic changes in genes are often caused by small-scale sequence changes in either the coding sequence or regulatory regions of a gene. All SNPs identified here are synonymous non-coding variants located within a region of 51 kb in intron 1. Additionally, we genotyped all known non-synonymous SNPs in the gene, but all were monomorphic. Thus, non-synonymous genetic variation could not explain the differences in outcome. It is unlikely that a single base change in an intronic region may alter the configuration of the gene product and the function of the protein. Therefore, we speculate that the SNPs identified may be in linkage with genetic variation at restriction sites, transcription sites in the promoter region, or in splicing sites. This was recently shown for the IL28B SNP rs12979860, which was found to be strongly linked to a genetic variant encoding a new interferon protein (interferon lambda 4). It was suggested that IFN-lambda 4 is a less potent IFN that lowers responsiveness to treatment with interferon-α [14]. Furthermore, non-coding SNPs may affect the expression of BCL2L1 by interfering with microRNA (miR). Guo et al. [15] showed that miR-16 is involved in the regulation
of apoptosis in activated hepatostellate cells by interfering with the expression of BCL2 and thereby mediating resistance to apoptosis.

Interestingly, the predictive value of BCL2L1 or IL28B exceeded the predictive value of non-genetic factors. Furthermore, the addition of the information conferred by the BCL2L1 polymorphism to the IL28B polymorphism resulted in a significant increase in the AUC for HCV genotype 1. As the introduction of DAAs in HCV treatment attenuated the impact of IL28B on SVR prediction [16–19], it is of interest to assess the impact of other host genetic predictors, such as BCL2L1, on SVR in triple therapy. Of note, the four pivotal GWASs on treatment-induced HCV clearance used seven different SNP genotyping arrays [20–23]. The BCL2L1 SNP rs1484994 is present on the Illumina Human1M-duo array used by Rauch et al. [21]. However, neither the rs1484994 SNP nor other SNPs in the BCL2L1 gene are among the top-20 SNPs reported to have significant association with SVR in HCV treatment.

The strengths of our study include the nationwide multi-centre design and population-based inclusion of study subjects. Moreover, our results were robust when corrected for multiple testing; however our study also has limitations. Despite the importance of fibrosis in predicting SVR, we were unable to adjust our analyses for fibrosis due to inconsistent reporting. Sensitivity analyses restricted to individuals with available information on fibrosis (n = 102) showed similar estimates of the effect of BCL2L1. The logistic regression was limited to the 182 individuals with available HCV VL within one year of treatment initiation. Our sensitivity analyses revealed a similar effect of BCL2L1, regardless of the availability of HCV VL measurements. We included patients with a minimum of 12 weeks of treatment to ensure that only non-responders with adequate drug exposure were evaluated. In the sensitivity analyses, the SVR estimates were comparable when we increased the minimum duration of treatment to 24 weeks.

In conclusion, our study suggests a role for polymorphisms in an apoptosis gene in the pegINF/RBV-mediated elimination of HCV. Our findings are preliminary and require replication in other cohorts and with treatment regimens including DAAs to further investigate the potential of this apoptosis gene in treatment response prediction.

4. Experimental Section

4.1. Study Subjects

Individuals were included from The Danish Database for Hepatitis B and C (DANHEP). DANHEP is a nationwide cohort study with ongoing enrollment and has previously been described [24]. Briefly, it contains demographic, clinical, and laboratory information on persons older than 16 years admitted to hospital with chronic hepatitis B virus (HBV) or HCV infection and who have been seen at least once after 1 January 2002, in one of the 16 medical departments that monitors and treats individuals with chronic hepatitis in Denmark. Inclusion criteria were (a) CHC defined as remaining HCV RNA positive for >6 months and (b) treatment naive individuals who had initiated treatment with pegylated interferon-α (PegIFN)/ribavirin (RBV) and with available blood samples for DNA extraction. Exclusion criteria were a positive HBV or HIV test, non-white European origin [25], participation in clinical trials, or inability to complete the first 12 weeks of treatment. Individuals were treated with pegIFN/RBV according to national guidelines [26–28]. Briefly, pegylated interferon α
(2a/2b) was administered weekly according to the manufacturer’s instructions; RBV was given daily, adjusted for body weight for HCV genotype 1, or as a “flat dosage” for genotype 3, according to the manufacturer’s instructions. The treatment duration was planned for 48 or 24 weeks for genotypes 1 or 3 respectively. In general, if HCV-RNA titres had not decreased by a minimum of 2 log values after 12 weeks, treatment was stopped according to international guidelines. SVR was defined as undetectable plasma HCV RNA at 24 weeks after treatment cessation. Relapse response (RR) was defined as undetectable HCV RNA during treatment but detectable in the follow-up period. Non-response (NR) was defined as detectable HCV RNA throughout treatment. The study was approved by the Danish Data Protection Agency (J.No. 2011-331-0514).

4.2. SNP Selection and Genotyping

SNPs were selected based on the following criteria: (1) all non-synonymous SNPs with known frequencies in a white European population; (2) synonymous SNPs located in the coding region at a minor allele frequency (MAF) >5% in a white European population; (3) synonymous SNPs located outside the coding region at an MAF >25% in a white European population from dbSNP [4]. SNP genotyping was performed in two rounds; after the initial genotyping according to the above-mentioned criteria, we performed another search for non-synonymous SNPs and included an additional 12 non-synonymous SNPs that were genotyped in 187 individuals for whom DNA was still available. The SNP genotyping was performed by KBioscience (KBioscience, Hertfordshire, UK) using a competitive allele-specific PCR [29].

4.3. Statistical Analyses

SNP frequencies were compared using the Chi² test or Fisher’s exact test, as appropriate. A false discovery rate (FDR) threshold of <0.05 was used to correct for multiple testing to minimise false-positive associations, corresponding to a significance level <0.003 for the highest ranking p-value (Table S1). SNPs fulfilling the criteria of an FDR < 0.05 were further considered in logistic regression analyses, which were adjusted for factors known to affect the rate of SVR (age and HCV viral load (VL) at treatment initiation and \textit{IL28B}). For determination of the ability of new SNPs to discriminate individuals with SVR from those without, we constructed receiver operating characteristic (ROC) curves and presented the areas under the curves (AUC) with 95% CI. We stratified all analyses according to HCV genotype. Relapsers and non-responders were merged into one non-response group for the analysis. HCV VL was log₁₀ transformed for the analysis. The results are presented using odds ratios (ORs) and adjusted ORs (aORs) with 95% confidence intervals (CIs). LD analysis was performed using Haploview 4.2 (Broad Institute of Harvard and MIT, Cambridge, MA, USA). All data were analysed using R (v.2.15.1, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) or Statistical Analysis Systems (SAS v. 9.3; SAS Institute, Cary, NC, USA).
5. Conclusions

In conclusion, our study suggests a role for polymorphisms in an apoptosis gene in the pegIFN/RBV-mediated elimination of HCV. Our findings are preliminary and require replication in other cohorts and with treatment regimens including DAAs to further investigate the potential of this apoptosis gene in treatment response prediction.

Supplementary Materials

Supplementary materials can be found at http://www.mdpi.com/1422-0067/16/02/3213/s1.

Acknowledgments

Financial support. This study was supported by a PhD scholarship from the Faculty of Health Sciences, University of Copenhagen (Louise Nygaard Clausen) and research grants from The Preben and Anna Simonsens Foundation (Louise Nygaard Clausen), The A.P. Møller Foundation for the Advancement of Medical Science (Nina Weis), The Novo Nordisk Foundation (Thomas Benfield), and The Lundbeck Foundation (Thomas Benfield).

Author Contributions

Louise Nygaard Clausen, Nina Weis and Thomas Benfield conceived the study and have made substantial contributions to design, analysis and interpretation of data and drafting the manuscript; Louise Nygaard Clausen, Nina Weis, Steen Ladelund, Lone Madsen, Britta Tarp, Peer Brehm Christensen, Henrik Bygum Krarup, Axel Møller, Jan Gerstoft, Mette Rye Clausen, TB have made substantial contributions to acquisition of data; Steen Ladelund made substantial contributions to analysis and interpretation of data. All authors contributed with a critical revision of the manuscript and read and approved the final manuscript. The Danish Database for Hepatitis B and C (DANHEP) group incl. Nina Weis, Suzanne Lunding, Lone Madsen, Britta Tarp, Peer Brehm Christensen, Henrik Bygum Krarup, Axel Møller, Jan Gerstoft and Mette Rye Clausen collected the data.

Appendix 1: Members of the DANHEP group. Nina Weis, Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre; Toke Barfod, Department of Infectious Diseases, Roskilde Hospital; Jens Bukh, Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre and Department of International Health, Immunology, and Microbiology, Faculty of Health Sciences, University of Copenhagen; Peer Brehm Christensen, Department of Infectious Diseases, Odense University Hospital; Mette Rye Clausen, Department of Hepatology, Copenhagen University Hospital, Rigshospitalet; Jan Gerstoft, Department of Infectious Diseases and Rheumatology, Copenhagen University Hospital, Rigshospitalet; Karin Groenbæk, Department of Gastroenterology, Copenhagen University Hospital, Hvidovre; Jesper Bach Hansen, Department of Gastroenterology, Aalborg University Hospital; Henrik Bygum Krarup, Department of Gastroenterology and Department of Clinical Biochemistry, Section for Molecular Diagnostics, Aalborg University Hospital; Kim Krogsgaard, The Brain Prize, COBIS; Alex Lund Laursen, Department of Infectious Diseases, Aarhus
University Hospital, Skejby; Jens Lindberg, Department of Internal Medicine, Herning Regional Hospital; Suzanne Lunding, Department of Infectious Diseases, Hilleroed Hospital; Lone Madsen, Department of Internal Medicine, Koege Hospital; Axel Moeller, Department of Internal Medicine, Kolding Regional Hospital; Henrik Nielsen, Department of Infectious Diseases, Copenhagen University Hospital; Peter Noerregaard, Department of Internal Medicine, Frederiksberg Hospital; Ove B. Schaffalitzky de Muckadell, Department of Gastroenterology, Odense University Hospital; Poul Schlichting, Department of Gastroenterology, Herlev University Hospital; Britta Tarp, Diagnostic Center, Silkeborg Regional Hospital; Reimar W. Thomsen, Department of Clinical Epidemiology, Aarhus University Hospital.

Conflicts of Interest

Nina Weis has been member of Advisory Boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Tibotec/Janssen Cilag and investigator for Bristol-Myers Squibb, Merck Sharp Dohme, and Tibotec/Janssen Cilag.

References

1. Mohd, H.K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. *Hepatology*** 2013, **57**, 1333–1342.

2. Fischer, R.; Baumert, T.; Blum, H.E. Hepatitis C virus infection and apoptosis. *World J. Gastroenterol.* **2007**, **13**, 4865–4872.

3. Canbay, A.; Friedman, S.; Gores, G.J. Apoptosis: The nexus of liver injury and fibrosis. *Hepatology*** 2004, **39**, 273–278.

4. TaqMan® SNP Genotyping Assays. Available online: http://www.ncbi.nlm.nih.gov/projects/SNP (accessed on 6 December 2014).

5. Chattopadhayay, K.; Ramagopal, U.A.; Mukhopadhaya, A.; Malashkevich, V.N.; Dilorenzo, T.P.; Brenowitz, M.; Nathenson, S.G.; Almo, S.C. Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function. *Proc. Natl. Acad. Sci. USA* **2007**, **104**, 19452–19457.

6. Liu, B.; Li, Z.; Mahesh, S.P.; Pantanelli, S.; Hwang, F.S.; Siu, W.O.; Nussenblatt, R.B. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. *J. Biol. Chem.* **2008**, **283**, 8202–8210.

7. Volkmann, X.; Cornberg, M.; Wedemeyer, H.; Lehner, F.; Manns, M.P.; Schulze-Osthoff, K.; Bantel, H. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. *Hepatology* **2006**, **43**, 1311–1316.

8. Schiavon, L.L.; Narciso-Schiavon, J.L.; Carvalho-Filho, R.J.; Sampaio, J.P.; El Batah, P.N.; Silva, G.A.; Carvente, C.T.; Silva, A.E.; Ferraz, M.L. Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy. *Antivir. Ther.* **2011**, **16**, 291–298.
9. Anatol, P.; Danuta, P.; Janusz, D.; Bozena, P. Expression of bcl-2 protein in chronic hepatitis C: Effect of interferon alpha 2b with ribavirin therapy. *World J. Gastroenterol.* **2005**, *11*, 2949–2952.

10. Shaker, O.G.; Eskander, E.F.; Yahya, S.M.; Mohamed, M.S.; Abd-Rabou, A.A. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. *Clin. Chim. Acta* **2011**, *412*, 593–598.

11. Lawitz, E.; Mangia, A.; Wyles, D.; Rodriguez-Torres, M.; Hassanein, T.; Gordon, S.C.; Schultz, M.; Davis, M.N.; Kayali, Z.; Reddy, K.R.; *et al.* Sofosbuvir for previously untreated chronic hepatitis C infection. *N. Engl. J. Med.* **2013**, *368*, 1878–1887.

12. Lawitz, E.; Poordad, F.; Brainard, D. Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: Results from the LONESTAR-2 study. In Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, USA, 1–5 November 2013.

13. Zeuzem, S.; Dusheiko, G.M.; Salupere R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: The VALENCE trial. In Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, USA, 1–5 November 2013.

14. Prokunina-Olsson, L.; Muchmore, B.; Tang, W.; Pfeiffer, R.M.; Park, H.; Dickensheets, H.; Hergott, D.; Porter-Gill, P.; Mumy, A.; Kohaar, I.; *et al.* A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. *Nat. Genet.* **2013**, *45*, 164–171.

15. Guo, C.J.; Pan, Q.; Jiang, B.; Chen, G.Y.; Li, D.G. Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. *Apoptosis* **2009**, *14*, 1331–1340.

16. Bota, S.; Sporea, I.; Sirli, R.; Neghina, A.M.; Popescu, A.; Strain, M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: A systematic review and meta-analysis. *Clin. Drug Investig.* **2013**, *33*, 325–331.

17. Holmes, J.A.; Desmond, P.V.; Thompson, A.J. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? *J. Viral Hepat.* **2012**, *19*, 677–684.

18. Muir, A.J. IL28B in the era of direct-acting antivirals for hepatitis C. *J. Clin. Gastroenterol.* **2013**, *47*, 222–227.

19. Thompson, A.J.; McHutchison, J.G. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? *Hepatology* **2012**, *56*, 373–381.

20. Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; *et al.* Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* **2009**, *461*, 399–401.

21. Rauch, A.; Kutalik, Z.; Descombes, P.; Cai, T.; Di, I.J.; Mueller, T.; Bochud, M.; Battegay, M.; Bernasconi, E.; Borovicka, J.; *et al.* Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. *Gastroenterology* **2010**, *138*, 1338–1345.
22. Suppiah, V.; Moldovan, M.; Ahlenstiel, G.; Berg, T.; Weltman, M.; Abate, M.L.; Bassendine, M.; Spengler, U.; Dore, G.J.; Powell, E.; et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41, 1100–1104.

23. Tanaka, Y.; Nishida, N.; Sugiyama, M.; Kurosaki, M.; Matsuura, K.; Sakamoto, N.; Nakagawa, M.; Korenaga, M.; Hino, K.; Hige, S.; et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41, 1105–1109.

24. Hansen, N.; Obel, N.; Christensen, P.B.; Krarup, H.; Laursen, A.L.; Clausen, M.R.; Lunding, S.; Moller, A.; Schlichting, P.; Kromann-Andersen, H.; et al. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: A Danish cohort study. J. Viral Hepat. 2009, 16, 659–665.

25. Cordell, H.J.; Clayton, D.G. Genetic association studies. Lancet 2005, 366, 1121–1131.

26. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Goncales, F.L.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975–982.

27. Hansen, N.; Obel, N.; Christensen, P.B.; Kjaer, M.; Laursen, A.L.; Krarup, H.B.; Moller, A.; Schlichting, P.; Bukh, J.; Weis, N. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. BMC Infect. Dis. 2011, 11, doi:10.1186/1471-2334-11-177.

28. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon α-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358, 958–965.

29. Nijman, I.J.; Kuipers, S.; Verheul, M.; Guryev, V.; Cuppen, E. A genome-wide SNP panel for mapping and association studies in the rat. BMC Genomics 2008, 9, doi:10.1186/1471-2164-9-95.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).